Monoclonal Antibodies to Endotoxin New Allies Against Sepsis?

Publisher Website
Google Scholar
Abstract
Both Greenman et al1and Ziegler et al2recently reported studies of major importance. Both studies found that monoclonal antibodies to endotoxin can reduce mortality and increase the reversal of multiorgan failure in some patients with gram-negative sepsis. This is welcome news, given that sepsis is increasing in incidence and its associated mortality remains high despite the use of potent antibiotics, fluid resuscitation, and vasoactive agents.3 Unfortunately, neither monoclonal antibody was effective in all patients to whom it was given, and each antibody was effective in a different subgroup of patients. Although their prices have not been announced, both products are expected to be costly. Thus, physicians will be faced with several dilemmas when these agents are approved for use. The first dilemma involves cost. I believe that monoclonal antibodies to endotoxin will prove to be extremely helpful in the management of gram-negative

This publication has 2 references indexed in Scilit: